Biopharma Co. Adds CTO to Team
Source: Francois Brisebois
September 22, 2023 (Investorideas.com Newswire) This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.
DiaMedica Therapeutics Inc. (DMAC:NASDAQ) appointed Dr. Ambarish Shah as its chief technology officer (CTO), reported Oppenheimer analyst Francois Brisebois in a September 12 research note.
"We view Dr. Shah's appointment as CTO to be significant in DMAC's current development stage," Brisebois commented.
The Minnesota-based biopharma is developing novel treatments for neurological disorders and cardio-renal disease.
Impressive Return Potential
Oppenheimer reiterated its Outperform rating and US$7 per share price target on DiaMedica, currently trading at about US$3.43 per share.
From this price, the return to target represents a potential return for investors that is compelling: 104%.
A Good Fit
Shah, who previously worked at Bristol Myers Squibb, AstraZeneca, GSK, and Pfizer, brings to DiaMedica extensive experience in protein development and manufacturing, reported Brisebois. Having helped advance more than 50 biologics through various stages of development, he has a solid track record.
The addition of Shah to DiaMedica's team comes at an important time for the company, Brisebois pointed out. It is preparing to restart the Phase 2/3 ReMEDy2 trial evaluating DM199, a recombinant protein replacement therapy designed to return KLK1 to normal levels, in acute ischemic stroke patients.
The investigational new drug application for the drug in this indication had been on clinical hold until recently. Before his appointment, Shah had advised DiaMedica about the final resolution of the hold.
"We expect to see the impact of [Shah's] expertise in the ReMEDy2 plans," Brisebois wrote.
Catalyst on the Horizon
The biopharma is expected to resume ReMEDy2 soon, and doing so could move up its stock price, Brisebois noted.
Going forward, the trial design will be simpler, with only one primary endpoint: stroke recovery. DiaMedica is working with a new contract research organization on site selection and finalizing the enrollment timeline. Full enrollment for an interim analysis should be achieved sometime next year.
"Given the clinical hold resolution, we anticipate DM199 to have a significant impact for acute ischemic stroke patients as study enrollment resumes," commented Brisebois.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/